SecBot SecBot
8-K ·Filed Sep 3, 2026

ABBV

AbbVie Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed2mo ago SEC0001104659-26-104940
8-K context-dependent: Items 7.01
Actionable Insight • Neutral

The completion is a routine closing event with no new financial surprises. Focus shifts to pipeline execution for zumilokibart (Phase 2 AD data) and APG273 (asthma development). Monitor upcoming clinical readouts and integration updates for potential catalysts.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

ABBV drug pipeline →

zumilokibart

◆ Mixed Named in this 8-K
Impact
Phase
Phase 2 complete (positive); Phase 3 planned/initiating 2H 2026
Time to market
Phase 3 initiation guided to 2H 2026 with a company-flagged potential 2029 commercial launch in atopic dermatitis — roughly 3 years from now, assuming Phase 3 success and a standard filing/PDUFA path.
Next catalyst
None dated

What to watchFor APGE holders, the drug's upside is essentially monetized, the stock trades ~0.7% below the $135.11 all-cash offer, so the remaining question is simply whether the AbbVie deal closes in Q3 2026 (mean analyst target $130.53 vs. price ~$134 reflects the capped upside). For AbbVie investors, zumilokibart is a 2030s thesis: watch Phase 3 initiation in atopic dermatitis (guided 2H 2026), interim data from the head-to-head versus Dupixent (2H 2026), and the ~$0.14 FY2026 EPS dilution the deal carries, the Phase 3 readouts that could validate the ~$10.9B price tag are years away.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$260.21
T+0 close · Sep 3, 2026 · via day close
Latest settled
+1.00%
T+20 · $262.82 · next T+60 in 13d
Vs SPY
+2.19%
α at T+20
Latest observation
+15.90%
T+49 · FF3 residual α
  1. T+0 · Sep 3 $260.21entry
  2. T+1 · 2mo ago −1.44%α −1.06% · $256.46
  3. T+5 · 2mo ago −1.19%α −0.04% · $257.12
  4. T+20 · 7w ago +1.00%α +2.19% · $262.82
  5. T+51 · todayOpen
  6. T+60 · in 13d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AbbVie completed its $10.9 billion acquisition of Apogee Therapeutics, adding late-stage immunology assets zumilokibart (atopic dermatitis) and APG273 (asthma). AbbVie reaffirmed its FY2026 adjusted EPS guidance of $13.87-$14.07 and Q3 guidance of $3.84-$3.88, with the deal expected to dilute EPS by $0.14 in 2026 and $0.46 in 2027 before becoming accretive in 2032.

Key Facts

  • Acquisition of Apogee Therapeutics completed for $135.11 per share in cash, total equity value ~$10.9 billion
  • Apogee's lead asset zumilokibart (IL-13 mAb) is in Phase 2 for atopic dermatitis with potential best-in-category profile
  • Pipeline includes APG273 (IL-13 + TSLP combination) in development for asthma
  • AbbVie reaffirms FY2026 adjusted diluted EPS guidance range $13.87-$14.07
  • AbbVie reaffirms Q3 2026 adjusted diluted EPS guidance range $3.84-$3.88
  • Deal expected to dilute adjusted EPS by $0.14 in 2026 (partial year) and ~$0.46 in 2027, with accretion beginning in 2032

Financial Impact

Total equity value ~$10.9 billion; EPS dilution of $0.14 in 2026 and ~$0.46 in 2027; accretion from 2032

epsrevenue (long-term pipeline)debt (cash consideration)

Risk Factors

  • Integration of Apogee's operations and pipeline may be more difficult or costly than anticipated
  • Clinical trial failure or regulatory setbacks for zumilokibart or APG273
  • Competition from existing IL-13/TSLP-targeting therapies (e.g., dupilumab, tezepelumab)

Market Snapshot

Price
$260.59
Volume
100
Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (39 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-104940
Document: tm2624674d1_ex99-1.htm0001104659-26-104940
Document: 0001104659-26-104940-index-headers.html0001104659-26-104940
Document: 0001104659-26-104940-index.html0001104659-26-104940
Document: 0001104659-26-104940.txt0001104659-26-104940

Track record

22 reports on ABBV

Performance horizon

7 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +27.21% at T+60 after the Apr 29, 2026 report. 7 of 9 went positive at some point.

Filters
  1. Nov 9, 20267d ago 144 Neutral 2/10 Entry $293.89 Now $294.55 +0.22% settles Dec 9
  2. Nov 2, 202614d ago 8-K Neutral 2/10 Entry $286.00 Now $294.55 +2.99% settles Dec 2
  3. Oct 30, 202617d ago 8-K Bullish 6/10 Entry $294.89 Now $294.55 −0.12% settles Nov 30
  4. Oct 29, 202619d ago Court Ruling Bullish 7/10 Entry $294.89 Now $294.55 −0.12% settles Nov 30
  5. Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $282.68 to $294.55 Now $294.55 +4.20% ▲ +4.20% +7.66% vs SPY
  6. Oct 15, 20264w ago 8-K Neutral 2/10 Entry $285.42 to $295.03 Now $294.55 +3.20% ▲ +3.37% +4.53% vs SPY
  7. Oct 5, 20266w ago 8-K Neutral 4/10 Entry $265.06 to $289.60 Now $294.55 +11.12% ▲ +9.26% +12.16% vs SPY
  8. Sep 28, 20267w ago Court Ruling Neutral 2/10 Entry $263.29 to $286.39 Now $294.55 +11.87% ▲ +8.77% +8.06% vs SPY
  9. Sep 14, 20269w ago Court Ruling Neutral Not scored Entry $261.43 to $272.69 Now $294.55 +12.67% ▲ +4.30% +1.33% vs SPY
  10. Sep 3, 202610w ago 8-K Neutral 4/10 Viewing Entry $260.21 to $262.82 Now $294.55 +13.20% ▲ +1.00% +2.19% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens Wed (11h 44m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 3, 2026